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Abstract
Background—The delta opioid receptor (DOR) is broadly expressed throughout the nervous 
system and regulates chronic pain, emotional responses, motivation and memory. Neural circuits 
underlying DOR activities have been poorly explored by genetic approaches. Here we used 
conditional mouse mutagenesis to elucidate receptor function in GABAergic neurons of the 
forebrain.
Methods—We characterized DOR distribution in the brain of Dlx5/6-CreXOprd1fl/fl (Dlx-DOR) 
mice, and tested main central DOR functions through behavioral testing.
Results—DORs proteins were strongly deleted in olfactory bulb and striatum, and remained 
intact in cortex and basolateral amygdala. Olfactory perception, circadian activity and despair-like 
behaviors were unchanged. In contrast, locomotor stimulant effects of SNC80 (DOR agonist) and 
SKF81297 (D1 agonist) were abolished and increased, respectively. Furthermore, Dlx-DOR mice 
showed lower levels of anxiety in the elevated plus-maze, opposing the known high anxiety in 
constitutive DOR knockout animals. Also Dlx-DOR mice reached the food more rapidly in a 
novelty suppressed feeding (NSF) task, despite their lower motivation for food reward observed in 
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an operant paradigm. Finally, c-fos staining after NSF was strongly reduced in amygdala, 
concordant with the low anxiety phenotype of Dlx-DOR mice.
Conclusion—Here we demonstrate that DORs expressed in the forebrain mediate the described 
locomotor effect of SNC80 and inhibit D1-stimulated hyperactivity. Our data also reveal an 
unanticipated anxiogenic role for this particular DOR subpopulation, with a potential novel 
adaptive role. DORs therefore exert dual anxiolytic/anxiogenic roles in emotional responses, 
which may both have implications in the area of anxiety disorders.
Keywords
Delta opioid receptor; Conditional gene knockout; GABAergic forebrain neurons; Locomotion; 
Motivation; Emotion
Introduction
Mu, delta and kappa opioid receptors are distributed throughout the nervous system and play 
a central role in pain control, hedonic homeostasis and emotions (1, 2). In the last decade, 
the delta opioid receptor (DOR) has emerged as an attractive target to reduce chronic pain 
(3, 4). This receptor is also a key player in several brain processes (5), including the 
regulation of emotional responses (6), impulsivity (7) or learning and memory (8), and has 
raised interest in both areas of neurologic and psychiatric disorders. Emotional responses 
represent a most important aspect of DOR function. Preclinical studies have established a 
general beneficial role for DOR in reducing levels of anxiety and depressive-like behavior, 
and delta agonists are in clinical trial for the treatment of mood disorders (3, 9).
DORs are broadly expressed in central and peripheral nervous systems. In the mouse, 
quantitative autoradiographic binding (10-12) shows particularly abundant protein levels in 
the olfactory bulb (OB), cortex, striatum and amygdala (Amy). Moderate DOR levels are 
also found in interpeduncular and pontine nuclei, hippocampus (Hipp), spinal cord (SC) and 
dorsal root ganglia (DRGs), and low levels in hypothalamus, thalamus, mesencephalon and 
brain stem (reviewed in (13)). A knock-in mouse line expressing functional fluorescent 
DORs (14) has allowed anatomical studies of DOR expression with cellular and subcellular 
details in DRGs (15), enteric neurons (15-18) and the Hipp (16, 17). Refined mapping of 
DOR expression in the mouse is now possible (19) and provides a basis for understanding 
DOR activities in the brain and periphery. Analyses of DOR distribution in the human brain 
shows expression concordant with rodent studies in cortical regions and limbic structures 
such as Hipp and Amy, as well as basal ganglia and hypothalamus (20-23).
At present, neuron populations and brain circuits where DORs operate in the nervous system 
have been poorly explored. In pain research, local pharmacology at the level of DRGs and 
SC has indicated a role for peripheral DORs in pain control (24), and a conditional genetic 
approach has demonstrated that DORs expressed in small primary nociceptive neurons are 
essential to reduce persistent pain and mediate delta opioid analgesia (25). In the brain, local 
pharmacology has provided evidence for an anxiolytic role of DORs at the level of cingulate 
cortex (Cg Cx) (26), Hipp (27) and Amy (28, 29). However neural populations engaged in 
DOR-mediated mood control have not been examined by genetic approaches, and DOR-
Chung et al. Page 2
Biol Psychiatry. Author manuscript; available in PMC 2016 February 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
mediated mechanisms underlying motivational and emotional responses, or learning and 
memory remain unexplored.
In this study we used a Dlx5/6 driver Cre line to genetically inactivate the DOR gene in 
forebrain GABAergic neurons. We obtained a conditional knockout mouse line that lacks 
receptors in two main DOR expression sites, i. e. the OB and striatum, including caudate 
putamen (CPu) and nucleus accumbens (NAc). These mice retain full receptor density in the 
basolateral amygdala (BLA), which represents a third main site with densest DOR protein 
levels. We then examined these mice in behaviors known to engage these brain structures 
and may recruit DOR-mediated controls. Our data reveal an unexpected anxiogenic role for 
this particular DOR population, which contrasts with the known overall anxiolytic role of 
the receptor.
Methods and Materials
Animals
The DOR-floxed (Oprd1fl/fl or Ctrl mice) mouse line was described previously (25). Mice 
were crossed with CMV-Cre mice or Dlx5/6-Cre mice to produce constitutive knockout 
(CMV-CreXOprd1fl/fl or CMV-DOR) and conditional knockout (Dlx5/6- Oprd1fl/fl or Dlx-
DOR) mouse lines, see details in Supplementary. For all behavioral experiment, the Dlx-
DOR mice are compared to their control littermates Ctrl mice. In addition, the CMV-DOR 
mice were also tested in the anxiety-related tests (see Supplementary). Experiments were 
performed on animals aged between 6 and 18 weeks old, housed 2-4 per cage under standard 
laboratory conditions (12h dark/light cycle light on at 7am). Food and water were available 
ad libitum. In the chocolate pellet self-administration experiment, we used males only. For 
other experiments, both males and females were used, and data were pooled since statistical 
analysis showed not significant gender effect. All experimental procedures were carried out 
in accordance with the European Communities Council Directive of 24 November 1986 
(86/609/EEC) and were approved by the local ethical committee (Comité d'éthique pour 
l'expérimentation animale IGBMC-ICS).
Quantitative Reverse Transcriptase-PCR
Sampling of brain regions, RNA extraction and quantification were performed according to 
a previous study (30, 31) and briefly described in Supplementary.
Autoradiographic Binding Assay
Sections were cut from Ctrl, Dlx-DOR and CMV-DOR brains (n = 3) for determination of 
total DOR binding using [3H] deltorphin-1 as the radiolabeled ligand. On the day of the 
experiment, sections were thawed and processed according to established protocols (32, 33), 
with minor modifications. Films exposure, development and analyze were performed as 
previously described by Kitchen et al. (33). Further details are described in Supplementary.
Agonist-Stimulated [35S]-GTPγS Binding Assays
Membrane preparations and [35S]GTPγS binding assays were performed on brain regions 
from Ctrl, Dlx-DOR and CMV-DOR mice as described (34) (see Supplementary).
Chung et al. Page 3
Biol Psychiatry. Author manuscript; available in PMC 2016 February 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Behavioral Assays
Locomotion, depressive-like behaviors (forced swim and tail suspension tests), anxiety-
related behaviors (light/dark box, elevated plus maze and open field tests), novelty-
suppressed feeding tests and food self-administration experiments were performed as 
described in Supplementary.
Drugs
The non-peptidic DOR agonist SNC80 and the dopamine D1 receptor agonist SKF-81297 
were used at doses according to previous studies (35, 36). See preparation in Supplementary.
c-Fos immunoreactivity
Measures of c-fos protein expression were performed as reported (37). Further details about 
sections processing are provided in Supplementary.
Statistical analysis
Statistical differences were determined by analysis of variance (ANOVA) (StatView 5, SAS 
Institute Inc., Cary, North Carolina) followed by Bonferroni/Dunn post hoc analysis. The F 
values and experimental degrees of freedom are included in the Results Section. For 
experiments with two groups, a Student t-test was used. The level of statistical significance 
was set at p < 0.05. For the behavioral tests during which data were obtained on several 
periods during the same session (locomotor tests, the Open Field test and despair-like 
behavior paradigms), the analysis of variance repeated measures was used.
Results
Dlx-DOR mice show DOR deletion mainly in OB and striatum
We used the Cre-LoxP strategy to inactivate the DOR gene (Oprdm1) in forebrain areas. 
Because DORs are mainly expressed in GABAergic neurons (17, 38, 39), we mated floxed-
DOR (Oprd1fl/fl) mice (25) with Dlx-Cre5/6 mice that express Cre recombinase in the 
forebrain GABAergic neurons (40) to produce conditional (Dlx5/6-Cre X Oprd1fl/fl or Dlx-
DOR) mutant mice. We first analyzed DOR transcripts throughout the nervous system using 
quantitative reverse transcriptase-PCR analysis (Fig. 1A). In mutant mice, DOR mRNA 
expression was undetectable in OB (OB) and striatum, including CPu and NAc, partially 
reduced in frontal cortex (FCx) and Amy, and showed normal levels in the spinal cord (SC), 
periaqueductal gray matter (PAG), brainstem (BS), dorsal raphe nucleus (DRN) and ventral 
tegmental area (VTA). The genetic deletion, therefore, impacts mainly forebrain areas, 
consistent with the Dlx5/6-Cre expression pattern ((40) and our unpublished data).
We next quantified DOR protein distribution in Dlx-DOR mice, using autoradiographic 
binding (Table 1 and Fig. 1B-D). There was a strong reduction of [3H] deltorphin-1 binding 
in external plexiform and internal granular layers of OB, as well as lateral and medial CPu 
and olfactory tubercles from Dlx-DOR mice. Significant reduction of DOR binding sites 
was also found in the NAc shell and CA2/3 regions of the Hipp. In contrast there was no 
significant modification of DOR binding sites throughout cortical areas and BLA 
subdivisions, and DOR protein levels were also unchanged at the level of SC. Densitometry 
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analysis of CMV-DOR samples confirmed complete DOR deletion in CMV-DOR mice 
throughout the nervous system.
To further confirm lack of protein activity, we measured DOR-mediated G protein activation 
in brain areas showing reduced receptor binding sites. As expected, agonist-induced [35S]-
GTPγS binding (Table S1) was abolished in membrane preparations from OB and CPu, 
decreased in the hippocampal preparation and comparable to controls in both FCx and SC 
samples. Receptor signaling therefore fully matches receptor binding in mutant mice.
Dlx-DOR mice show altered locomotor responses to DOR and D1/D3 DAR agonists
We first examined whether DOR loss in CPu and NAc leads to changes in spontaneous 
locomotor activity and feeding behavior (Table 2). Analysis of total locomotor activity 
during light (F (2, 20) = 0.31; p>0.05, one-way ANOVA) and dark (F (2, 20) = 0.8; p>0.05, 
one-way ANOVA) phases revealed no significant difference between Dlx-DOR and control 
mice. Similarly, no difference in number of distributed food pellets was detected between 
genotypes (F (2, 20) = 2.05; p>0.05, oneway ANOVA).
We then examined locomotor stimulant effects of the prototypal DOR agonist, SNC80 (41) 
in Dlx-DOR mice (Fig 2A) in actimetry cages. Habituation was similar across genotypes 
(data not shown). SNC80 treatment (10 mg/kg) induced the expected locomotor stimulation 
in control mice but was inefficient in Dlx-DOR mice. Two-way ANOVA revealed a 
significant effect of treatment (F (1, 32) = 16.37; p<0.001) and genotype (F (1, 32) = 7.10; 
p<0.001), and significant treatment × genotype interaction (F (2, 32) = 5.25; p<0.05). Post 
hoc analysis confirmed that SNC80 treatment significantly enhanced locomotor activity in 
Ctrl (p<0.001, Bonferroni/Dunn test) but not in Dlx-DOR mice (p>0.05, Bonferroni/Dunn 
test). Targeted deletion of DORs in forebrain GABAergic neurons therefore abolishes the 
locomotor stimulant effect of SNC80.
To further explore integrity of the basal ganglia circuitry, we examined locomotor stimulant 
effects of SKF-81297, a D1 dopamine receptor agonist (Fig 2B). At a low dose (1 mg/kg), 
SKF-81297 induced a locomotor stimulation in both control and Dlx-DOR mice 
(F(1, 37)=8.63; p<0.01), with no significant difference between genotypes (F (1, 37) = 0.02; 
p>0.05, Two-way ANOVA). At high dose (2.5 mg/kg), SKF-81297 induced a locomotor 
stimulation in control animals and this stimulant effect was potentiated in Dlx-DOR mice. 
Two-way ANOVA performed on total activity scores showed significant effect of treatment 
(F (1, 37) = 22.23; p<0.0001) and significant genotype × treatment interaction (F (1, 37) = 
5.54; p<0.05). Post hoc analysis confirmed that 2.5 mg/kg SKF-81297 stimulates Dlx-DOR 
mice significantly more than controls (p<0.001, Bonferroni/Dunn test). Thus, selective 
inactivation of DORs in forebrain GABAergic neurons potentiates D1/D3 dopamine 
receptor function.
Dlx-DOR mice show reduced levels of anxiety
Our earlier work revealed a depressive-like phenotype in constitutive DOR knockout mice 
(6). Dlx-DOR mice show major receptor loss in OB and NAc, two areas associated with 
altered mood (42)((43). We therefore tested Dlx-DOR mice for olfactory discrimination, as 
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well as despairlike behaviors in forced swim and tail suspension tests. Mutant mice behaved 
similarly to control littermates in all these tasks (Supplementary Results and Figure S1).
Previous work also indicated that constitutive DOR knockout mice show enhanced 
anxietylike behavior (6, 44). Many brain structures contribute to anxiety-associated 
responses, including the Amy (45) and forebrain areas (46) where DORs have either 
remained intact (Amy) or been deleted (striatum, Hipp) in Dlx-DOR mice. We tested 
whether the strong DOR depletion in forebrain but not Amy would produce an anxiety-
related phenotype (Figure 3). In the open field, Dlx-DOR mice did not differ from controls 
for both general activity (t (30) = 0.38, p>0.05, Student t-test) and time spent in the arena 
center (t (30) = 0.17, p>0.05, Student t-test) (Figure 3A). In the elevated plus-maze test, 
however, a behavioral phenotype was detectable (Figure 3B). Dlx-DOR mice displayed 
lower anxiety-related behavior compared to controls, as shown by increased time spent in 
open arms (t (30) = 2.31, p<0.05, Student t-test). Mutant mice also tended to make more 
entries into open arms, although this effect did not reach statistical significance (t (30) = 1.44, 
p>0.05, Student t-test). The number of entries in closed arms, an index of locomotor activity, 
was otherwise unchanged (Ctrl: 11.75 ± 0.72 and Dlx-DOR: 11.19 ±0.79; t (30) = 1.16, 
p>0.05, Student's t-test). Thus, mice lacking DORs in forebrain GABAergic neurons display 
lower levels of anxiety, a phenotype that opposes the described increased anxiety-like 
behaviors in constitutive DOR knockout mice.
To further examine this unexpected phenotype, we tested Dlx-DOR mice in the novelty 
suppressed feeding (NSF) task (Figure 3C). In this paradigm, low latency to start eating in a 
novel environment reflects reduced anxiety-related behavior (47, 48). Dlx-DOR mice 
showed a shorter latency to feed compared to controls (t (34) = -3.38, p<0.01, Student t-test) 
and made fewer approaches (t (34) = -5.00, p<0.001, Student t-test). Both parameters, 
therefore, indicate strong behavioral modifications in mutant mice, consistent with lower 
anxiety observed in the elevated plus-maze.
The phenotype observed in NSF may partly result from increased motivation to obtain the 
food. However, the amount of food pellets consumed was similar between both groups in 
actimetry cages (Table 2), suggesting that regular food consumption is unchanged in mutant 
mice. To further test motivation for food in Dlx-DOR mice, we examined motivation to eat 
palatable chocolate-flavoured pellets in a self-administration (SA) paradigm (Figure 4). 
Mice from both genotypes discriminated between active and inactive holes during most of 
the training period, and active nose-poking increased across days (Figure 4A). Control and 
mutant mice acquired and maintained operant responding similarly in both fixed ratio 1 
(FR1) and fixed ratio 5 (FR5) schedules. Number of pellets consumed did not differ between 
genotypes, as revealed by the two-way ANOVA analysis showing significant effects of day 
(F(14,518) = 70.37; p<0.001), no main effect of genotype (F(1,37) = 0.29; p>0.05) and no 
interaction between genotype and day (F(14,518) = 0.76; p>0.05). In addition, both genotypes 
expressed similar levels of active nose-poking during FR1 (Figure 4C, 72.30 ± 5.45 in Ctrl 
and 72.38 ± 5.61 in Dlx-DOR mice) and FR5 (629.29 ± 32.68 in Ctrl and 603.21 ± 39.84 in 
Dlx-DOR mice) reinforced phases (see Table S2 for three-way ANOVA). The targeted DOR 
deletion in Dlx-DOR mice, therefore, does not modify operant responding to food reward.
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In contrast, breaking point values were significantly decreased in Dlx-DOR mice compared 
to control littermates (F(1,37) = 6.88; p < 0.05) in the progressive ratio (PR) schedule of 
reinforcement (Figure 4B). Mutant mice, therefore, show reduced motivation for chocolate-
flavoured pellets, suggesting that DOR deletion in forebrain GABAergic neurons diminishes 
motivation for food reward. Altogether, our observations that Dlx-DOR mice show normal 
food consumption (actimetry boxes), normal acquisition of chocolate pellet self-
administration (SA, FR1 and FR5) and reduced motivation for these pellets (SA, PR), 
strongly suggest that increased motivation for food does not contribute to the low anxiety 
behavior of Dlx-DOR mice in the NSF task.
Dlx-DOR mice show abnormal neuronal activity in cortex, Amy and NAc following novelty 
suppressed feeding test
C-fos protein expression is routinely used as a marker of neuronal activity (49). To gain 
insight into circuit mechanisms underlying the hypoanxiety phenotype of Dlx-DOR mice, 
we assessed Fos protein expression following animal exposure to the NSF task (Table 3). In 
a control experiment, c-fos immunoreactivity did not differ across genotypes under basal 
conditions (Table S3). Also, 24h deprivation alone induced similar c-fos staining in Dlx-
DOR and control littermates, except at the level of NAc (t (2) = 8.46, p<0.05, Student t-test) 
and insular cortex (Ins Cx) (t (2) = 6.4 3, p<0.05, Student t-test) where a food-related 
response may contribute to distinguish mutant and control mice. After NSF, mutant mice 
showed a significant decrease of c-fos immunostaining in several brain regions associated to 
the central integration of emotional components of aversive stimuli, including the Ins Cx (t
(14) = 3.04, p<0.01, Student t-test), BLA (t (12) = 3.21, p<0.01, Student t-test) and central 
nuclei of the amygdala (CeA) (t (12) = 4.56, p<0.001, Student t-test). On the other hand, a 
significant increase of c-fos protein expression was found in NAc, interfacing emotion, 
motivation and action. C-Fos expression was otherwise unchanged in all subregions of the 
CPu, the Cg Cx (Cg Cx), the basomedial nucleus of the amygdala and ventral tegmental area 
(VTA). Together, the data show that targeted DOR deletion in forebrain GABAergic 
neurons leads to distinct neuronal activation in mutant and control mice after NSF, which 
occur mainly in BLA and CeA. Decreased c-fos activation in these two brain regions is 
consistent with the low anxiety behavior of mutant mice in the task.
Discussion
We used Dlx5/6-Cre mice to target the DOR gene in forebrain GABAergic neurons, and 
obtained conditional knockout mice with a strong deletion of DORs in OB and striatum, 
while the receptor was preserved in the cortex, BLA, more rostral brain areas and SC. 
Behavioral analysis of mutant mice provide first genetic evidence that DORs expressed in 
these brain areas inhibit D1R-mediated locomotor activity and motivation for food reward. 
Additionally, our study uncovered a novel role for DOR in the regulation of anxiety-related 
behaviors.
The driver Dlx5/6-Cre mouse line was used previously to delete CB1 receptors from 
GABAergic neurons of the forebrain (40). Based on the notion that opioid receptors are 
mostly expressed in GABAergic neurons (16, 17), we anticipated strong decrease of DOR 
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mRNA expression and protein levels throughout the forebrain. Indeed, DORs were almost 
entirely deleted in OB and striatum. Residual DOR protein in CPu and NAc may arise from 
DOR protein expression in striatal cholinergic interneurons, or may reflect presynaptic 
receptors on glutamatergic neurons that mainly project from cortex and Amy to the striatum 
(50-52). DOR mRNA and protein deletion was otherwise partial in Hipp, and protein levels 
were fully preserved in cortical areas and Amy. We cannot exclude that, in the latter two 
areas, limited DOR deletion in discrete neuron populations occurred but was not detected by 
our methods. In these brain areas also, remaining or intact receptor protein expression could 
be explained by partial Cre-mediated excision, although in our hands, crossing Dlx5/6-Cre 
mice with ROSA26 reporter mice showed strong Cre activity at these sites (data not shown). 
Alternatively, DOR protein expression may occur in non-GABAergic neurons in these brain 
regions, or could be synthesized and transported from more posterior brain structures. In 
support of this, Amy showed decreased DOR mRNA, indicating local Cre-mediated DOR 
gene excision. However, DOR protein levels were maintained, suggesting that the majority 
of amygdalar receptors are localized presynaptically on afferent terminals. Finally, ectopic 
Cre expression has been reported in non-GABAergic neurons of hypothalamic areas in 
Dlx5/6-Cre mice (53), however this did not seem to impact Dlx-DOR mice that show intact 
DOR protein levels in the hypothalamus (Table 1).
Constitutive DOR knockout mice show enhanced spontaneous locomotor activity (6). We 
did not observe a similar phenotype in Dlx-DOR mice, suggesting that this particular DOR 
activity is not regulated at the level of GABAergic forebrain neurons, or simply could not be 
detected under our experimental conditions. We further observed that the described SNC80-
induced hyperlocomotion effect (36, 54) is abolished in Dlx-DOR mice, demonstrating that 
targeted DORs are essential for the known stimulant effects of the agonist. It is likely that 
this DOR activity operates at the level of striatum, which plays a prominent role in 
locomotor activity (55) and shows most effective DOR deletion in conditional mutant mice. 
Finally, we found potentiated SKF-81297-induced hyperactivity in mutant mice. We have 
previously reported that constitutive DOR gene knockout and DOR blockage by systemic 
DOR antagonist treatment, both produce a similar higher sensitivity to SKF-stimulating 
effects (35). Together with the present study, the data suggest that DORs expressed in 
striatal GABAergic neurons exert a tonic suppressive effect on striatonigral D1 pathways 
and the associated locomotor response. Whether DOR/D1R interactions occur directly at the 
level of D1R-expressing medium spiny neurons or via intrastriatal microcircuitry remains to 
be determined.
Modified dopaminergic signaling in Dlx-DOR mice may also impact responses to rewarding 
outcomes. We found that operant responding for palatable food is unchanged in Dlx-DOR 
mice under FR1 and FR5 schedules. We previously showed that morphine self-
administration is preserved in constitutive DOR knockout mice (56), and together the data 
suggest that DORs do not play a major role in opioid or food reward. However, we found in 
this study that Dlx-DOR mice show slightly decreased motivation for food reward in a PR 
schedule. Although DORs overall do not seem to regulate food reward, it is possible that 
DORs in forebrain GABAergic neurons contribute to some aspects of motivational 
processes, a hypothesis that deserves further investigations.
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DORs were fully removed from the OB in Dlx-DOR mice. We found, however, no main 
alteration in basic olfactory perception, suggesting that DORs in the OB are not necessary to 
the detection of olfactory stimuli. Olfactory bulbectomy is a classical model of despair-like 
behavior (57), and we speculated that Dlx-DOR mice may show a despair-like phenotype, as 
do constitutive DOR knockout mice (6). Under our experimental conditions however, 
mutant mice showed no sign of despair behaviour, suggesting that DORs do not tonically 
regulate emotional circuits associated to OB circuitry and olfaction. Despair-like behaviour 
in constitutive DOR KO mice therefore, likely results from lack of receptor activity in other 
brain circuits. It will be interesting to assess Dlx-DOR mice reactivity to stressful odors or in 
other olfactory tests (Odor-dependent memory and odor detection threshold tasks), in order 
to determine whether DOR plays any role in olfactory circuitry where the receptor is most 
densely expressed. In addition, it may be of interest to examine whether the reported 
SNC80-induced antidepressant effect (58) is altered in the Dlx-DOR mice, to determine 
whether systemic pharmacological activation recruits forebrain DOR circuits to alleviate 
depressive-like behaviors.
Dlx-DOR mice show an intriguing low anxiety phenotype. Although no modification of 
anxiety levels was detected in the open field, mutant mice spent significantly more time in 
open arms of the elevated plus-maze and showed strongly reduced latency to reach the food 
in the NSF test, despite their reduced motivation to obtain a food reward in the SA 
paradigm. The Dlx-DOR mouse phenotype in elevated plus-maze and NSF reflects reduced 
anxiety-related behavior. The absence of detectable phenotype in the open field may relate 
to distinct stress levels applied in the different paradigms (e.g. novelty, brightness, openness, 
privation, elevation (59, 60)). This particular behavior of mutant mice may be more obvious 
under specific stress conditions, such as food deprivation stress in the case of NSF. 
Importantly, c-fos analysis immediately after this task further supports the notion of reduced 
anxiety taking in mutant mice. Thus, neural activation was reduced mainly in lateral and 
central divisions of the Amy, consistent with a reduced response to anxiogenic stimuli (61, 
62). In sum, the data strongly suggest that DORs expressed in GABAergic forebrain neurons 
normally contribute to increase anxiety. One may speculate that this particular DOR activity, 
which has not been reported earlier, could contribute to exert an adaptive protective role 
under threatening situations.
The low anxiety phenotype of Dlx-DOR mice was unexpected, and opposes the established 
high anxiety-related behavior reported for constitutive DOR KO animals (6, 44). Previous 
studies, indeed, have shown that total DOR gene knockout and systemic DOR antagonist 
treatment both increase levels of anxiety (6, 28, 58, 63, 64), while systemic DOR agonists 
reduce levels of anxiety (58, 64, 65), demonstrating a prevailing anxiolytic DOR activity. 
Further, local administration of DOR agonists and antagonist in the amygdala support a 
main contribution of amygdala DORs in this anxiolytic activity (29). A simple interpretation 
of our data is that DORs exert both anxiolytic and anxiogenic activities, at distinct level of 
neural circuits possibly involving midbrain (including amygdala) and forebrain structures, 
respectively. Anxiolytic DOR activity predominates in wild-type animals and is absent in 
total knockout animals. Anxiogenic DOR activity otherwise has been deleted in Dlx-DOR 
animals only, which leads to anxiety levels lower than wild-type in these animals, at least in 
EPM and NSF testing. Future experiments will be required to substantiate this hypothesis.
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In conclusion, previous conditional gene knockout studies for cannabinoid CB1 (40) and 
corticotrophin-releasing hormone receptor 1 (66) have revealed antagonistic receptor 
activities, which operate in separate neural networks. Using a similar approach, our study 
reports a novel anxiogenic DOR activity that engages forebrain GABAergic neurons, 
possibly at the level of corticostriatal networks tightly connecting the Amy (52, 67), a 
hypothesis that will be tested in future studies. The discovery of dual anxiolytic/anxiogenic 
roles for DORs, opens novel perspectives in the area of DOR function and anxiety disorders.
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Fig. 1. Neuroanatomical characterization of Dlx-DOR mice
(A) Quantitative RT-PCR. DOR mRNA levels were measured in microdissected samples 
from Control (Ctrl, white bars), Dlx-DOR (conditional mutant, grey bars) and CMV-DOR 
(constitutive mutant, black bars) mice (n=3-4/group). Data were normalized using the 
housekeeping gene 36B4. Expression levels of mutants are expressed as percent change 
compared to control levels. The DOR transcript was undetectable in OB, CPu and NAc, 
partially decreased in FCx, Hipp and Amy and unchanged in SC, PAG, BS, DRN and VTA 
of Dlx-MOR mice, and was undetectable overall in CMV-DOR mice. (B-C) Quantitative 
DOR ligand binding autoradiography. Brain sections were labeled with [3H] deltorphin-1 
and all sections were processed in parallel throughout binding and development of 
autoradiograms. Representative autoradiograms from brain (B) and SC (C) sections are 
shown for the three genotypes. The color bar code shows a pseudo-colour interpretation of 
relative densities from black and white images calibrated in fmol/mg tissue. Non-specific 
binding was homogenous and at background levels. Values and statistics are shown in Table 
1. (D) Summary of DOR protein levels in Dlx-DOR mice compared to control mice, adapted 
from Table 1. Regions in orange correspond to brain areas showing significant reduction of 
DOR protein, and numbers represent percent change of DOR protein levels in conditional 
mutant mice from Table 1. Abbreviations: Amy, amygdala; Cg, cingulated cortex; BS, 
brainstem; CPu, caudate-putamen nucleus; DRN, dorsal raphe nucleus; FCx, frontal cortex; 
Hipp, hippocampus; NAc, nucleus accumbens; OB, olfactory bulb; PAG, periaqueducatal 
gray; RS, retrosplenial cortex; SC, spinal cord; VTA, ventral tegmental area.
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Fig. 2. DOR and D1-mediated locomotor activity
Dlx-DOR mice and their control littermates (Ctrl) were tested in actimetry boxes for 
responses to (A) the DOR agonist SNC80 or (B) the dopamine D1 agonist SKF81297. (A) 
Left panel shows locomotor activity in Ctrl and Dlx-DOR mice treated by intraperitoneal 
injection of SNC80 (10 mg/kg) or saline over a 2H session, and right panel shows total 
activity. Activity was significantly increased in SNC80-treated control mice only (n= 8-10 
per genotype and treatment). (B) In a second cohort, SKF-81297 was administered 
subcutaneously (at 1 or 2.5 mg/kg doses). Both Dlx-DOR mice and their control littermates 
(Ctrl) showed increased locomotor activity compared to vehicle-treated mice, and this effect 
was significantly stronger in Dlx-DOR mice at the high dose (left, time course; right total 
activity; n = 9-11 mice per genotype and treatment). Filled and open stars indicate 
significant treatment or genotype effect, respectively. One star, P<0.05; three stars, P<0.001 
(Two-way ANOVA).
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Fig. 3. Anxiety-related behaviours
(A) Open Field. Distance travelled (left) and time spent in center (right) did not differ across 
genotypes. (B) Elevated plus-maze. Dlx-DOR showed increased time in open arms (left) and 
a trend to more entries in those arms (right) compared to Ctrl mice. General activity was 
similar (total visits) between the two groups (data not shown), reflecting no change in 
spontaneous locomotor activity. (C) Novelty suppressed feeding. Latency to feed was 
decreased (left), and accordingly number of approaches was decreased also (right) in Dlx-
DOR mice compared with Ctrl mice. n=16 per genotype, and filled stars represent 
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significant differences compare to Ctrl mice. One star, P<0.05; two stars, P<0.01; three 
stars, P<0.001 (Student t-test).
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Fig. 4. Chocolate flavoured pellets self-administration
(A) Acquisition and maintenance. Mean number of active and inactive nose-pokes during 10 
days of FR1, 5 days of FR5 and 10 days of extinction in 1 h daily sessions. (B) Motivation. 
Mean breaking point achieved in a session of progressive ratio that was conducted once and 
lasted 5 h. (C) Cue-induced reinstatement. Mean number of active nose-pokes during the 
different experimental phases: mean of the 3 days of the acquisition criteria of chocolate 
self-administration during FR1 and FR5, mean of the 3 days of the acquisition of the 
extinction criteria and cue-induced reinstatement. Ctrl (n = 23) and Dlx-DOR mice (n = 16). 
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Data are expressed as mean ± SEM. One star, P<0.05; two stars, P<0.01 comparison 
between genotypes (three-way ANOVA).
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Table 2
Basal locomotor activity in control (Ctrl), conditional (Dlx-DOR) and total (CMV-DOR) 
knockout
Total locomotor activity was automatically recorded during 20h (from 3 P.M. to 11 A.M.) in actimetry boxes. 
Values represent the number of infrared beams crossed for the whole session, the light period (8h) or the dark 
period (12h). There were no statistical differences. CMV-DOR mice showed a trend towards an increased 
locomotor activity as compared to Ctrl and Dlx-DOR mice. Number of food pellets distributed during the 
session was measured and no difference was detected. n= 8 per genotype. Statistical analysis was performed 
using one-way ANOVA.
Genotype Total locomotor activity During light period (8h) During night period (12h) Nb of distributed food pellets
Ctrl 4850.43 ± 1282.05 2246.29 ± 583.2 2604.14 ±707.94 288 ± 10.59
Dlx-DOR 5306.80 ± 851.83 2208.6 ± 353.72 3098.20 ± 514.76 303.3 ± 35.43
CMV-DOR 6606.33 ± 2013.84 2476 ± 703.48 4130.33 ± 1320.1 209.5 ± 41.96
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